Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.

Abstract

PET imaging with radiolabeled drugs provides information on tumor uptake and dose-dependent target interaction to support selection of an optimal dose for future efficacy testing. In this immuno-PET study of the anti-human epidermal growth factor receptor (HER3) mAb GSK2849330, we investigated the biodistribution and tumor uptake of 89Zr-labeled GSK2849330 and evaluated target engagement as a function of antibody mass dose. Methods:89Zr-GSK2849330 distribution was monitored in 6 patients with HER3-positive tumors not amenable to standard treatment. Patients received 2 administrations of 89Zr-GSK2849330. Imaging after tracer only was performed at baseline; dose-dependent inhibition of 89Zr-GSK2849330 uptake in tumor tissues was evaluated 2 wk later using increasing doses of unlabeled GSK2849330 in combination with the tracer. Up to 3 PET scans (2 hours post infusion [p.i.] and days 2 and 5 p.i.) were performed after tracer administration. Biodistribution and tumor targeting were assessed visually and quantitatively using SUV. The 50% and 90% inhibitory mass doses (ID50 and ID90) of target-mediated antibody uptake were calculated using a Patlak transformation. Results: At baseline, imaging with tracer showed good tumor uptake in all evaluable patients. Predosing with unlabeled mAb reduced the tumor uptake rate in a dose-dependent manner. Saturation of 89Zr-mAb uptake by tumors was seen at the highest dose (30 mg/kg). Despite the limited number of patients, an exploratory ID50 of 2 mg/kg and ID90 of 18 mg/kg have been determined. Conclusion: In this immuno-PET study, dose-dependent inhibition of tumor uptake of 89Zr-GSK2849330 by unlabeled mAb confirmed target engagement of mAb to the HER3 receptor. This study further validates the use of immuno-PET to directly visualize tissue drug disposition in patients with a noninvasive approach and to measure target engagement at the site of action, offering the potential for dose selection.

• Authors: C Willemien Menke-van der Houven van Oordt, Adam McGeoch, Mats Bergstrom, Iain McSherry, Deborah A Smith, Matthew Cleveland, Wasfi Al-Azzam, Liangfu Chen, Henk Verheul, Otto S Hoekstra, Danielle J Vugts, Immanuel Freedman, Marc Huisman, Chris Matheny, Guus van Dongen, Sean Zhang
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 60 Issue 7 Pg. 902-909 (07 2019) ISSN: 1535-5667 [Electronic] United States
• PMID: 30733323 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Chemical References

• Antibodies, Monoclonal, Humanized
• GSK2849330
• Radioisotopes
• Zirconium
• Receptor, ErbB-3
• Zirconium-89

Topics

• Adult
• Antibodies, Monoclonal, Humanized (adverse effects, immunology, pharmacokinetics)
• Dose-Response Relationship, Immunologic
• Female
• Humans
• Male
• Middle Aged
• Neoplasms (diagnostic imaging, immunology, pathology)
• Positron-Emission Tomography
• Radioisotopes
• Receptor, ErbB-3 (immunology)
• Safety
• Tissue Distribution
• Zirconium